CDK4 and breast cancer: In a large pooled FDA group analysis [21], Gao et al. investigated all the phase 3 randomized BC trials of CDK4/6i plus endocrine therapy to see whether any clinical-pathological ABC subgroups benefited from the addition of a CDK4/6i to endocrine therapy.